May 1990

Live Attenuated and Inactivated Influenza Vaccine in School-age Children

Author Affiliations

From the Influenza Research Center, Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Tex (Drs Gruber, Taber, Glezen, Demmler, and Couch); and the Department of Family Medicine, University of Oklahoma, Oklahoma City (Drs Clover and Abell). Dr Gruber is now with Vanderbilt University, Nashville, Tenn.

Am J Dis Child. 1990;144(5):595-600. doi:10.1001/archpedi.1990.02150290089035

• In 1985, we enrolled 189 school-age children by family in a double-blind study to determine protection against influenza by a single dose of cold-recombinant bivalent A vaccine or commercial trivalent inactivated vaccine compared with placebo. All children in school or day care, 3 to 18 years of age, in an enrolled family received the same preparation. Following vaccination, 60% and 21% of cold-recombinant bivalent A vaccine recipients and 73% and 83% of trivalent inactivated vaccine recipients demonstrated fourfold or greater response in hemagglutination-inhibition antibody titer to A/H1N1 and A/H3N2, respectively. Sixty-seven percent of all trivalent inactivated vaccine recipients demonstrated a fourfold or greater serologic response to H1N1, H3N2, and influenza B following a single dose of vaccine. During the 1985-1986 influenza B/Ann Arbor epidemic, heterotypic protection afforded by the influenza B/USSR component of trivalent inactivated vaccine was 62% compared with placebo. A single dose of trivalent inactivated vaccine protected schoolage children, 6 to 19 years of age, from influenza B infection; the rate of protection was 64% against infection and 73% against febrile illness.

(AJDC. 1990;144:595-600)